Up a level |
Sharman, Jeff P, Coutre, Steven E, Furman, Richard R, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian W et al (show 14 more authors)
(2019)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Journal of Clinical Oncology, 37 (16).
pp. 1391-1402.
Kreuzer, Karl-Anton, Furman, Richard R, Stilgenbauer, Stephan, Dubowy, Ronald L, Kim, Yeonhee, Munugalavadla, Veerendra, Lilienweiss, Esther, Reinhardt, Hans Christian, Cramer, Paula, Eichhorst, Barbara et al (show 4 more authors)
(2020)
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
Leukemia, 34 (1).
pp. 296-300.